Literature DB >> 26274375

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells.

Ariosto Silva1, Timothy Jacobson2, Mark Meads2, Allison Distler2, Kenneth Shain2.   

Abstract

In this work we describe a novel approach that combines ex vivo drug sensitivity assays and digital image analysis to estimate chemosensitivity and heterogeneity of patient-derived multiple myeloma (MM) cells. This approach consists in seeding primary MM cells freshly extracted from bone marrow aspirates into microfluidic chambers implemented in multi-well plates, each consisting of a reconstruction of the bone marrow microenvironment, including extracellular matrix (collagen or basement membrane matrix) and stroma (patient-derived mesenchymal stem cells) or human-derived endothelial cells (HUVECs). The chambers are drugged with different agents and concentrations, and are imaged sequentially for 96 hr through bright field microscopy, in a motorized microscope equipped with a digital camera. Digital image analysis software detects live and dead cells from presence or absence of membrane motion, and generates curves of change in viability as a function of drug concentration and exposure time. We use a computational model to determine the parameters of chemosensitivity of the tumor population to each drug, as well as the number of sub-populations present as a measure of tumor heterogeneity. These patient-tailored models can then be used to simulate therapeutic regimens and estimate clinical response.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26274375      PMCID: PMC4544963          DOI: 10.3791/53070

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  13 in total

1.  Assessment of bone marrow plasma cell infiltrates in multiple myeloma: the added value of CD138 immunohistochemistry.

Authors:  Samer Z Al-Quran; Lijun Yang; James M Magill; Raul C Braylan; Vonda K Douglas-Nikitin
Journal:  Hum Pathol       Date:  2007-08-21       Impact factor: 3.466

2.  Preparation of cells for microscopy using cytospin.

Authors:  Cheryl M Koh
Journal:  Methods Enzymol       Date:  2013       Impact factor: 1.600

Review 3.  The role of complete response in multiple myeloma.

Authors:  Jean-Luc Harousseau; Michel Attal; Herve Avet-Loiseau
Journal:  Blood       Date:  2009-07-28       Impact factor: 22.113

4.  Fluorescence-based experimental model to evaluate the concomitant effect of drugs on the tumour microenvironment and cancer cells.

Authors:  Karthik Ramasamy; Hazera Khatun; Lee Macpherson; Mathew P Caley; Justin Sturge; Ghulam J Mufti; Stephen A Schey; Yolanda Calle
Journal:  Br J Haematol       Date:  2012-03-20       Impact factor: 6.998

5.  A preclinical assay for chemosensitivity in multiple myeloma.

Authors:  Zayar P Khin; Maria L C Ribeiro; Timothy Jacobson; Lori Hazlehurst; Lia Perez; Rachid Baz; Kenneth Shain; Ariosto S Silva
Journal:  Cancer Res       Date:  2013-12-05       Impact factor: 12.701

Review 6.  50 years of preclinical anticancer drug screening: empirical to target-driven approaches.

Authors:  Marie Suggitt; Michael C Bibby
Journal:  Clin Cancer Res       Date:  2005-02-01       Impact factor: 12.531

7.  Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in southwest oncology group chemotherapy trials.

Authors:  Brian G M Durie; Joth Jacobson; Bart Barlogie; John Crowley
Journal:  J Clin Oncol       Date:  2004-04-26       Impact factor: 44.544

8.  A unique three-dimensional model for evaluating the impact of therapy on multiple myeloma.

Authors:  Julia Kirshner; Kyle J Thulien; Lorri D Martin; Carina Debes Marun; Tony Reiman; Andrew R Belch; Linda M Pilarski
Journal:  Blood       Date:  2008-06-05       Impact factor: 22.113

9.  Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs.

Authors:  S E Salmon; A W Hamburger; B Soehnlen; B G Durie; D S Alberts; T E Moon
Journal:  N Engl J Med       Date:  1978-06-15       Impact factor: 91.245

10.  Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity.

Authors:  Douglas W McMillin; Jake Delmore; Ellen Weisberg; Joseph M Negri; D Corey Geer; Steffen Klippel; Nicholas Mitsiades; Robert L Schlossman; Nikhil C Munshi; Andrew L Kung; James D Griffin; Paul G Richardson; Kenneth C Anderson; Constantine S Mitsiades
Journal:  Nat Med       Date:  2010-03-14       Impact factor: 53.440

View more
  15 in total

1.  PLK1 stabilizes a MYC-dependent kinase network in aggressive B cell lymphomas.

Authors:  Yuan Ren; Chengfeng Bi; Xiaohong Zhao; Tint Lwin; Cheng Wang; Ji Yuan; Ariosto S Silva; Bijal D Shah; Bin Fang; Tao Li; John M Koomen; Huijuan Jiang; Julio C Chavez; Lan V Pham; Praneeth R Sudalagunta; Lixin Wan; Xuefeng Wang; William S Dalton; Lynn C Moscinski; Kenneth H Shain; Julie Vose; John L Cleveland; Eduardo M Sotomayor; Kai Fu; Jianguo Tao
Journal:  J Clin Invest       Date:  2018-11-05       Impact factor: 14.808

Review 2.  Bioprinting and Organ-on-Chip Applications Towards Personalized Medicine for Bone Diseases.

Authors:  Chiara Arrigoni; Mara Gilardi; Simone Bersini; Christian Candrian; Matteo Moretti
Journal:  Stem Cell Rev Rep       Date:  2017-06       Impact factor: 5.739

3.  BCL2 Amplicon Loss and Transcriptional Remodeling Drives ABT-199 Resistance in B Cell Lymphoma Models.

Authors:  Xiaohong Zhao; Yuan Ren; Matthew Lawlor; Bijal D Shah; Paul M C Park; Tint Lwin; Xuefeng Wang; Kenian Liu; Michelle Wang; Jing Gao; Tao Li; Mousheng Xu; Ariosto S Silva; Kaplan Lee; Tinghu Zhang; John M Koomen; Huijuan Jiang; Praneeth R Sudalagunta; Mark B Meads; Fengdong Cheng; Chengfeng Bi; Kai Fu; Huitao Fan; William S Dalton; Lynn C Moscinski; Kenneth H Shain; Eduardo M Sotomayor; Gang Greg Wang; Nathanael S Gray; John L Cleveland; Jun Qi; Jianguo Tao
Journal:  Cancer Cell       Date:  2019-05-13       Impact factor: 31.743

4.  IAP and HDAC inhibitors interact synergistically in myeloma cells through noncanonical NF-κB- and caspase-8-dependent mechanisms.

Authors:  Liang Zhou; Yu Zhang; Mark B Meads; Yun Dai; Yanxia Ning; Xiaoyan Hu; Lin Li; Kanika Sharma; Jewel Nkwocha; Rebecca Parker; Danny Bui; Jacquelyn McCarter; Lora Kramer; Cullen Purcell; Praneeth R Sudalagunta; Rafael R Canevarolo; Maria D Coelho Siqueira Silva; Gabriel De Avila; Raghunandan Reddy Alugubelli; Ariosto S Silva; Maciej Kmeiciak; Andrea Ferreira-Gonzalez; Kenneth H Shain; Steven Grant
Journal:  Blood Adv       Date:  2021-10-12

Review 5.  Targeting Intrinsic and Extrinsic Vulnerabilities for the Treatment of Multiple Myeloma.

Authors:  Nagaraju Anreddy; Lori A Hazlehurst
Journal:  J Cell Biochem       Date:  2016-06-21       Impact factor: 4.429

6.  Venetoclax as a single agent and in combination with PI3K-MTOR1/2 kinase inhibitors against ibrutinib sensitive and resistant mantle cell lymphoma.

Authors:  Huijuan Jiang; Tint Lwin; Xiaohong Zhao; Yuan Ren; Grace Li; Lynn Moscinski; Bijal Shah; Jianguo Tao
Journal:  Br J Haematol       Date:  2018-01-30       Impact factor: 6.998

Review 7.  Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment.

Authors:  Taiga Nishihori; Jinming Song; Kenneth H Shain
Journal:  Curr Hematol Malig Rep       Date:  2016-04       Impact factor: 3.952

8.  Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma.

Authors:  Xiaohong Zhao; Tint Lwin; Ariosto Silva; Bijal Shah; Jiangchuan Tao; Bin Fang; Liang Zhang; Kai Fu; Chengfeng Bi; Jiannong Li; Huijuan Jiang; Mark B Meads; Timothy Jacobson; Maria Silva; Allison Distler; Lancia Darville; Ling Zhang; Ying Han; Dmitri Rebatchouk; Maurizio Di Liberto; Lynn C Moscinski; John M Koomen; William S Dalton; Kenneth H Shain; Michael Wang; Eduardo Sotomayor; Jianguo Tao
Journal:  Nat Commun       Date:  2017-04-18       Impact factor: 14.919

9.  MTI-101 treatment inducing activation of Stim1 and TRPC1 expression is a determinant of response in multiple myeloma.

Authors:  Michael F Emmons; Nagaraju Anreddy; Javier Cuevas; Kayla Steinberger; Shengyu Yang; Mark McLaughlin; Ariosto Silva; Lori A Hazlehurst
Journal:  Sci Rep       Date:  2017-06-02       Impact factor: 4.379

10.  A pharmacodynamic model of clinical synergy in multiple myeloma.

Authors:  Praneeth Sudalagunta; Maria C Silva; Rafael R Canevarolo; Raghunandan Reddy Alugubelli; Gabriel DeAvila; Alexandre Tungesvik; Lia Perez; Robert Gatenby; Robert Gillies; Rachid Baz; Mark B Meads; Kenneth H Shain; Ariosto S Silva
Journal:  EBioMedicine       Date:  2020-04-05       Impact factor: 8.143

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.